AMES Treatment of the Impaired Leg in Chronic Stroke Patients

NCT ID: NCT01378637

Last Updated: 2016-12-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE1/PHASE2

Total Enrollment

22 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-01-31

Study Completion Date

2017-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this protocol is to determine if individuals who had a stroke more than one year before entering the study and whose ankles remain substantially impaired are able to sense and move the affected leg better after 9-13 weeks of treatment with a robotic therapy device (AMES).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Our research objective is to develop procedures to rehabilitate those stroke patients who, through conventional therapies, are not brought to a level of maximal recovery. The aims of the proposed project are to obtain a set of data from a total of 20 chronic stroke subjects, all with severe lower extremity disability, between the ages of 18-85, using a robotic therapeutic device placed in a rehabilitation clinic. This data will allow us to quantify the extent to which a combination of robotic-assisted exercise and tendon vibration from the AMES beta device induces secondary recovery from the effects of stroke on the lower extremity.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Stroke Cerebrovascular Accident Hemiparesis

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Leg Robotic device AMES Stroke Cerebrovascular Accident Rehabilitation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

AMES Leg treatment

An investigational device flexes and extends the ankle over a range of 30 degrees while vibrators stimulate the tendons attached to muscles that move the foot. The subject's task is to assist the motion of the device by pulling or pushing with the foot. Feedback of ankle torque or the electrical signal produced by the muscles (EMG) while the subject is assisting the motion is provided during the 30 treatment sessions.

Group Type EXPERIMENTAL

AMES- Leg treatment

Intervention Type DEVICE

30 minutes of treatment of the leg consisting of the AMES device passively moving the ankle between plantarflexion and dorsiflexion with vibration of the tendons being stretched, while the participant tries to assist in the movement as much as possible.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AMES- Leg treatment

30 minutes of treatment of the leg consisting of the AMES device passively moving the ankle between plantarflexion and dorsiflexion with vibration of the tendons being stretched, while the participant tries to assist in the movement as much as possible.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Spastic hemiparesis
* At least 12 months post-stroke
* Can comfortably fit foot in treatment device
* Functioning proprioception
* Fugl-Meyer LE score \>6 and \<23
* Minimal hemi-neglect
* Observable volitional movement of the ankle in either plantar- or dorsi-flexion
* Cognitively and behaviorally capable of complying with the regimen

Exclusion Criteria

* Fractures of treated limb resulting in loss of range of motion
* Spinal cord injury
* Deep venous thrombosis
* Peripheral nerve injury or neuropathy in the affected limb with motor disability
* Osteoarthritis limiting range of motion
* Uncontrolled high blood pressure/angina
* Exercise intolerant
* Skin condition not tolerant of device
* Progressive neurodegenerative disorder
* Uncontrolled seizure disorder
* Botox treatment within last 5 months
* Baclofen pump
Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Oregon Health and Science University

OTHER

Sponsor Role collaborator

Northwestern University

OTHER

Sponsor Role collaborator

Shirley Ryan AbilityLab

OTHER

Sponsor Role collaborator

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

Sponsor Role collaborator

AMES Technology

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Barry Oken, MD

Role: PRINCIPAL_INVESTIGATOR

Oregon Health and Science University

Elliot Roth, MD

Role: PRINCIPAL_INVESTIGATOR

Northwestern University/Rehabilitation Institute of Chicago

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Northwestern University/Rehabilitation Institute of Chicago

Chicago, Illinois, United States

Site Status

Oregon Health and Science University

Portland, Oregon, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

R44NS060192-03

Identifier Type: NIH

Identifier Source: secondary_id

View Link

7034

Identifier Type: -

Identifier Source: org_study_id